BioLineRx Stock Pattern Recognition Identical Three Crows
| BLRX Stock | USD 2.67 0.03 1.14% |
| Symbol |
Recognition |
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was twelve with a total number of output elements of forty-nine. The function did not return any valid pattern recognition events for the selected time horizon. The Identical Three Crows pattern describes BioLineRx trend with bearish reversal signal.
BioLineRx Technical Analysis Modules
Most technical analysis of BioLineRx help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for BioLineRx from various momentum indicators to cycle indicators. When you analyze BioLineRx charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About BioLineRx Ltd
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modiin, Israel. Biolinerx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 38 people. As a micro-cap equity, BioLineRx is reviewed for growth durability, margin stability, and risk discipline. Current metrics include P/B of 0.61, profit margin of -45.34%. BioLineRx has market cap of 15.18 M, ROE of -45.94%.
Methodology
Unless otherwise specified, financial data for BioLineRx is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. BioLineRx (USA Stocks:BLRX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Macroaxis analytics incorporate public filings and market reference sources and official disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Data harmonization may result in minor timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
BioLineRx may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards BioLineRx in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, BioLineRx's short interest history, or implied volatility extrapolated from BioLineRx options trading.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Macroaxis Index Invested few shares | |
 | Warren Buffett Holdings Invested over 60 shares | |
 | Momentum Invested few shares | |
 | FinTech Invested over 20 shares | |
 | Video Games Invested few shares | |
 | Hedge Favorites Invested over 200 shares | |
 | Investor Favorites Invested over 200 shares | |
 | Cash Cows Invested few shares |
More Resources for BioLineRx Stock Analysis
Reviewing BioLineRx commonly begins with financial statements and performance trends. Financial ratios provide context for profitability, efficiency, and growth trends. Selected reports below provide context for BioLineRx Stock:BioLineRx has market cap of 15.18 M, operating margin of -7.58%, ROE of -45.94%. See Trending Equities for portfolio-level analysis. This suggests a position in BioLineRx within the allocation view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. Our How to Buy BioLineRx Stock guide explains the steps to invest in BioLineRx stock.Analysis related to BioLineRx should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Portfolio Holdings module to check your current holdings and cash position to determine if your portfolio needs rebalancing.
Earnings Share -6.00 | Revenue Per Share | Quarterly Revenue Growth -0.94 | Return On Assets | Return On Equity |
Understanding BioLineRx includes distinguishing between market value and book value, where book value reflects BioLineRx accounting equity. BioLineRx's market capitalization is 15.18 M. A P/B ratio of 0.61 suggests BioLineRx trades near or below book value. Intrinsic value is an estimate of underlying worth, separate from trading price and book value. The valuation process compares these measures for perspective.
The concept of value for BioLineRx differs from its quoted price, since each reflects a different lens. For BioLineRx, key inputs include a P/B ratio of 0.61, a profit margin of -45.34%, ROE of -45.94%, and revenue of 28.94 M. Trading price represents the transaction level agreed by market participants.